{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:51:40Z","timestamp":1792511500167,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14486-1","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T03:12:31Z","timestamp":1751339551000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prospective phase II study of stereotactic body proton therapy for treatment of primary renal cell carcinoma (SPARE): clinical trial protocol"],"prefix":"10.1186","volume":"25","author":[{"given":"Sherif G","family":"Shaaban","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirmish","family":"Singla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anh","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suqi","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W","family":"Jarrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtiland","family":"Deville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"14486_CR1","unstructured":"The Surveillance E. and End Results Program. Cancer Stat Facts: Kidney and Renal Pelvis Cancer. 2024. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/kidrp.html."},{"issue":"6","key":"14486_CR2","doi-asserted-by":"publisher","first-page":"635","DOI":"10.6004\/jnccn.2009.0044","volume":"7","author":"DY Chen","year":"2009","unstructured":"Chen DY, Uzzo RG. Optimal management of localized renal cell carcinoma: surgery, ablation, or active surveillance. J Natl Compr Canc Netw. 2009;7(6):635\u201342. quiz 643.","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"14486_CR3","doi-asserted-by":"publisher","first-page":"667","DOI":"10.21873\/anticanres.15525","volume":"42","author":"DELA Pinta","year":"2022","unstructured":"Pinta DELA, Latorre C, Fuentes RG. SBRT in localized renal carcinoma: A review of the literature. Anticancer Res. 2022;42(2):667\u201374.","journal-title":"Anticancer Res"},{"issue":"6","key":"14486_CR4","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.eururo.2022.06.017","volume":"82","author":"M Ali","year":"2022","unstructured":"Ali M, Mooi J, Lawrentschuk N, McKay RR, Hannan R, Lo SS, Hall WA, Siva S. The role of stereotactic ablative body radiotherapy in renal cell carcinoma. Eur Urol. 2022;82(6):613\u201322.","journal-title":"Eur Urol"},{"issue":"4","key":"14486_CR5","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.eururo.2006.03.021","volume":"50","author":"L Walsh","year":"2006","unstructured":"Walsh L, Stanfield JL, Cho LC, Chang CH, Forster K, Kabbani W, Cadeddu JA, Hsieh JT, Choy H, Timmerman R, Lotan Y. Efficacy of ablative high-dose-per-fraction radiation for implanted human renal cell cancer in a nude mouse model. Eur Urol. 2006;50(4):795\u2013800.","journal-title":"Eur Urol"},{"issue":"21","key":"14486_CR6","doi-asserted-by":"publisher","first-page":"7985","DOI":"10.1158\/0008-5472.CAN-04-1525","volume":"64","author":"CT Garnett","year":"2004","unstructured":"Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res. 2004;64(21):7985\u201394.","journal-title":"Cancer Res"},{"issue":"1","key":"14486_CR7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1006\/scbi.2001.0405","volume":"12","author":"LE French","year":"2002","unstructured":"French LE, Tschopp J. Defective death receptor signaling as a cause of tumor immune escape. Semin Cancer Biol. 2002;12(1):51\u20135.","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"14486_CR8","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1182\/blood-2009-02-206870","volume":"114","author":"Y Lee","year":"2009","unstructured":"Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, Beckett M, Sharma R, Chin R, Tu T, Weichselbaum RR, Fu YX. Therapeutic effects of ablative radiation on local tumor require CD8\u2009+\u2009T cells: changing strategies for cancer treatment. Blood. 2009;114(3):589\u201395.","journal-title":"Blood"},{"issue":"7","key":"14486_CR9","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1158\/0008-5472.CAN-10-2820","volume":"71","author":"BC Burnette","year":"2011","unstructured":"Burnette BC, Liang H, Lee Y, Chlewicki L, Khodarev NN, Weichselbaum RR, Fu YX, Auh SL. The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity. Cancer Res. 2011;71(7):2488\u201396.","journal-title":"Cancer Res"},{"issue":"4","key":"14486_CR10","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/CJI.0b013e318163628c","volume":"31","author":"S Teitz-Tennenbaum","year":"2008","unstructured":"Teitz-Tennenbaum S, Li Q, Okuyama R, Davis MA, Sun R, Whitfield J, Knibbs RN, Stoolman LM, Chang AE. Mechanisms involved in radiation enhancement of intratumoral dendritic cell therapy. J Immunother. 2008;31(4):345\u201358.","journal-title":"J Immunother"},{"issue":"4","key":"14486_CR11","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.ijrobp.2010.09.034","volume":"81","author":"EL Kachikwu","year":"2011","unstructured":"Kachikwu EL, Iwamoto KS, Liao YP, DeMarco JJ, Agazaryan N, Economou JS, McBride WH, Schaue D. Radiation enhances regulatory T cell representation. Int J Radiat Oncol Biol Phys. 2011;81(4):1128\u201335.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"14486_CR12","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1080\/02841860802123196","volume":"47","author":"C Svedman","year":"2008","unstructured":"Svedman C, Karlsson K, Rutkowska E, Sandstr\u00f6m P, Blomgren H, Lax I, Wers\u00e4ll P. Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney. Acta Oncol. 2008;47(8):1578\u201383.","journal-title":"Acta Oncol"},{"issue":"6","key":"14486_CR13","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1097\/01.coc.0000145289.57705.07","volume":"27","author":"JJ Beitler","year":"2004","unstructured":"Beitler JJ, Makara D, Silverman P, Lederman G. Definitive, high-dose-per-fraction, conformal, stereotactic external radiation for renal cell carcinoma. Am J Clin Oncol. 2004;27(6):646\u20138.","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"14486_CR14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.radonc.2005.03.022","volume":"77","author":"PJ Wers\u00e4ll","year":"2005","unstructured":"Wers\u00e4ll PJ, Blomgren H, Lax I, K\u00e4lkner KM, Linder C, Lundell G, Nilsson B, Nilsson S, N\u00e4slund I, Pisa P, Svedman C. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol. 2005;77(1):88\u201395.","journal-title":"Radiother Oncol"},{"issue":"9","key":"14486_CR15","doi-asserted-by":"publisher","first-page":"e109","DOI":"10.1016\/j.clon.2016.04.002","volume":"28","author":"JH Chang","year":"2016","unstructured":"Chang JH, Cheung P, Erler D, Sonier M, Korol R, Chu W. Stereotactic ablative body radiotherapy for primary renal cell carcinoma in Non-surgical candidates: initial clinical experience. Clin Oncol (R Coll Radiol). 2016;28(9):e109\u201314.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"5","key":"14486_CR16","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/bju.13811","volume":"120","author":"S Siva","year":"2017","unstructured":"Siva S, Pham D, Kron T, Bressel M, Lam J, Tan TH, Chesson B, Shaw M, Chander S, Gill S, Brook NR, Lawrentschuk N, Murphy DG, Foroudi F. Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial. BJU Int. 2017;120(5):623\u201330.","journal-title":"BJU Int"},{"issue":"6","key":"14486_CR17","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.euf.2019.06.002","volume":"5","author":"RJM Correa","year":"2019","unstructured":"Correa RJM, Louie AV, Zaorsky NG, Lehrer EJ, Ellis R, Ponsky L, Kaplan I, Mahadevan A, Chu W, Swaminath A, Hannan R, Onishi H, Teh BS, Muacevic A, Lo SS, Staehler M, Siva S. The emerging role of stereotactic ablative radiotherapy for primary renal cell carcinoma: a systematic review and meta-analysis. Eur Urol Focus. 2019;5(6):958\u201369.","journal-title":"Eur Urol Focus"},{"issue":"12","key":"14486_CR18","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/S1470-2045(22)00656-8","volume":"23","author":"S Siva","year":"2022","unstructured":"Siva S, Ali M, Correa RJM, Muacevic A, Ponsky L, Ellis RJ, Lo SS, Onishi H, Swaminath A, McLaughlin M, Morgan SC, Cury FL, Teh BS, Mahadevan A, Kaplan ID, Chu W, Grubb W, Hannan R, Staehler M, Warner A, Louie AV. 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the international radiosurgery consortium of the Kidney). Lancet Oncol. 2022;23(12):1508\u201316.","journal-title":"Lancet Oncol"},{"issue":"3","key":"14486_CR19","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.eururo.2023.02.016","volume":"84","author":"R Hannan","year":"2023","unstructured":"Hannan R, McLaughlin MF, Pop LM, Pedrosa I, Kapur P, Garant A, Ahn C, Christie A, Zhu J, Wang T, Robles L, Durakoglugil D, Woldu S, Margulis V, Gahan J, Brugarolas J, Timmerman R, Cadeddu J. Phase 2 trial of stereotactic ablative radiotherapy for patients with primary renal cancer. Eur Urol. 2023;84(3):275\u201386.","journal-title":"Eur Urol"},{"issue":"3","key":"14486_CR20","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/S1470-2045(24)00020-2","volume":"25","author":"S Siva","year":"2024","unstructured":"Siva S, Bressel M, Sidhom M, Sridharan S, Vanneste BGL, Davey R, Montgomery R, Ruben J, Foroudi F, Higgs B, Lin C, Raman A, Hardcastle N, Hofman MS, De Abreu Lourenco R, Shaw M, Mancuso P, Moon D, Wong LM, Lawrentschuk N, Wood S, Brook NR, Kron T, Martin J, Pryor D; FASTRACK II Investigator Group. Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial. Lancet Oncol. 2024;25(3):308\u201316.","journal-title":"Lancet Oncol"},{"issue":"6","key":"14486_CR21","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3390\/cancers9060066","volume":"9","author":"O Mohamad","year":"2017","unstructured":"Mohamad O, Sishc BJ, Saha J, Pompos A, Rahimi A, Story MD, Davis AJ, Kim DWN. Carbon ion radiotherapy: a review of clinical experiences and preclinical research, with an emphasis on DNA damage\/repair. Cancers (Basel). 2017;9(6): 66.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"14486_CR22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/acm2.12308","volume":"19","author":"A Baydoun","year":"2018","unstructured":"Baydoun A, Vapiwala N, Ponsky LE, Awan M, Kassaee A, Sutton D, Podder TK, Zhang Y, Dobbins D, Muzic RF Jr, Traughber B, Machtay M, Ellis R. Comparative analysis for renal stereotactic body radiotherapy using cyberknife, VMAT and proton therapy based treatment planning. J Appl Clin Med Phys. 2018;19(3):125\u201330.","journal-title":"J Appl Clin Med Phys"},{"issue":"5","key":"14486_CR23","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.21873\/invivo.12116","volume":"34","author":"N Fukumitsu","year":"2020","unstructured":"Fukumitsu N, Ishikawa H, Arimura T, Wada H, Okimoto T, Sato Y, Iwata H, Shimizu S, Sakurai H. Proton therapy for primary renal cell carcinoma: the first nationwide retrospective study in Japan. In Vivo. 2020;34(5):2883\u20139.","journal-title":"In Vivo"},{"issue":"10","key":"14486_CR24","first-page":"e1799","volume":"9","author":"MA Frick","year":"2017","unstructured":"Frick MA, Chhabra AM, Lin L, Simone CB 2nd. First ever use of proton stereotactic body radiation therapy delivered with curative intent to bilateral synchronous primary renal cell carcinomas. Cureus. 2017;9(10):e1799.","journal-title":"Cureus"},{"issue":"3","key":"14486_CR25","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.ijrobp.2024.04.066","volume":"120","author":"M Gaudreault","year":"2024","unstructured":"Gaudreault M, Hardcastle N, Jackson P, McIntosh L, Higgs B, Pryor D, Sidhom M, Dykyj R, Moore A, Kron T, Siva S. Dose-effect relationship of kidney function after SABR for primary renal cell carcinoma: TROG 15.03 fastrack II. Int J Radiat Oncol Biol Phys. 2024;120(3):648\u201354.","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14486-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14486-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14486-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T03:12:33Z","timestamp":1751339553000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14486-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14486"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14486-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Clinical Research Review Committee and the Institutional Review Boards of Johns Hopkins University School of Medicine: #00427823. All participants enrolled in the trial will be required to provide written informed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Competing interests"}}],"article-number":"1107"}}